FULGENT GENETICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
FULGENT GENETICS, INC. (FLGT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $203.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was -$7.00K.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $210.00K.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $541.00K.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $579.00K, a 50.00% decline from fiscal 2024.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.16M, a 56.48% decline from fiscal 2023.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.66M, a 5017.31% increase from fiscal 2022.
- FULGENT GENETICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $52.00K, a 97.11% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $203.00K 10-Q · filed 2026-07-30 | $744.00K derived: sum of 3 quarters · filed 2026-07-30 | $744.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $210.00K 10-Q · filed 2026-05-01 | $751.00K derived: sum of 2 quarters · filed 2026-05-01 | $751.00K derived: sum of 3 quarters · filed 2026-05-01 | |
| 2025-12-31 | $541.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $541.00K derived: sum of 2 quarters · filed 2026-02-27 | $579.00K 10-K · filed 2026-02-27 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $38.00K 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $38.00K 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.16M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.16M 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $1.15M 10-Q · filed 2025-08-01 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $2.66M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $2.66M 10-Q · filed 2024-11-08 | ||
| 2023-06-30 | $2.66M 10-Q · filed 2024-08-02 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $52.00K 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $52.00K 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.03M derived: sum of 2 quarters · filed 2024-02-28 | $1.43M derived: sum of 3 quarters · filed 2024-02-28 | $1.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $941.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.34M derived: sum of 2 quarters · filed 2022-11-07 | $1.71M 10-Q · filed 2022-11-07 | $1.72M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $765.00K 10-Q · filed 2022-08-04 | $774.00K derived: sum of 3 quarters · filed 2023-02-28 | $774.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $368.00K 10-Q · filed 2022-05-05 | $377.00K derived: sum of 2 quarters · filed 2023-02-28 | $377.00K derived: sum of 3 quarters · filed 2023-02-28 | $770.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.00K derived: sum of 2 quarters · filed 2023-02-28 | $402.00K derived: sum of 3 quarters · filed 2023-02-28 | $402.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $393.00K derived: sum of 2 quarters · filed 2021-11-09 | $393.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $393.00K 10-Q · filed 2020-08-05 | $393.00K 10-Q · filed 2021-08-10 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $110.00K derived: sum of 2 quarters · filed 2022-02-28 | $110.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $110.00K 10-Q · filed 2020-11-09 | $110.00K 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |